Jeffrey Farrow - Tarsus Pharmaceuticals CFO Officer
| TARS Stock | USD 49.97 0.06 0.12% |
CFO
Jeffrey Farrow is CFO Officer of Tarsus Pharmaceuticals
| Age | 62 |
| Address | 15440 Laguna Canyon Road, Irvine, CA, United States, 92618 |
| Phone | 949 409 1801 |
| Web | https://www.tarsusrx.com |
Jeffrey Farrow Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jeffrey Farrow against Tarsus Pharmaceuticals stock is an integral part of due diligence when investing in Tarsus Pharmaceuticals. Jeffrey Farrow insider activity provides valuable insight into whether Tarsus Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Tarsus Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Tarsus Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jeffrey Farrow 3 days ago Disposition of 1186 shares by Jeffrey Farrow of Tarsus Pharmaceuticals at 50.11 subject to Rule 16b-3 | ||
Jeffrey Farrow few days ago Disposition of 1254 shares by Jeffrey Farrow of Tarsus Pharmaceuticals at 47.4 subject to Rule 16b-3 | ||
Jeffrey Farrow few days ago Disposition of 8019 shares by Jeffrey Farrow of Tarsus Pharmaceuticals subject to Rule 16b-3 |
Tarsus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2346) % which means that it has lost $0.2346 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5483) %, meaning that it created substantial loss on money invested by shareholders. Tarsus Pharmaceuticals' management efficiency ratios could be used to measure how well Tarsus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2025. Return On Capital Employed is likely to drop to -0.43 in 2025. At this time, Tarsus Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 15.4 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 114 M in 2025.Similar Executives
| Found 8 records | CFO Age | ||
| John CPA | Centessa Pharmaceuticals PLC | 51 | |
| MD MBA | Centessa Pharmaceuticals PLC | 54 | |
| Daniel MBA | Opthea | 67 | |
| Matt Zuga | Acumen Pharmaceuticals | N/A | |
| David JD | Pharvaris BV | 71 | |
| Jotin MD | Ikena Oncology | 45 | |
| Jonathan MBA | Rallybio Corp | 55 | |
| Jennifer Fox | Nuvation Bio | 52 | |
Management Performance
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.23 |
Tarsus Pharmaceuticals Leadership Team
Elected by the shareholders, the Tarsus Pharmaceuticals' board of directors comprises two types of representatives: Tarsus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tarsus. The board's role is to monitor Tarsus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Tarsus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tarsus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Farrow, CFO Officer | ||
| Leonard JD, Chief Officer | ||
| Scott Youmans, Vice Sales | ||
| Seshadri Neervannan, Chief Officer | ||
| Adrienne Kemp, Senior Communications | ||
| Elizabeth MD, Chief Director | ||
| Aziz MBA, Chief Officer | ||
| Neera Clase, Senior Access | ||
| David Nakasone, Head Relations | ||
| Matthew MBA, Vice Marketing | ||
| Michael Ackermann, CoFounder Board | ||
| Jeffrey CPA, CFO Officer | ||
| Bobak MD, President, CoFounder | ||
| Dianne MSW, Chief Officer | ||
| Cara Miller, Senior Affairs | ||
| MD JD, General Secretary |
Tarsus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tarsus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (0.63) % | ||||
| Operating Margin | (0.37) % | ||||
| Current Valuation | 1.84 B | ||||
| Shares Outstanding | 41.19 M | ||||
| Shares Owned By Insiders | 8.28 % | ||||
| Shares Owned By Institutions | 91.72 % | ||||
| Number Of Shares Shorted | 7.08 M | ||||
| Price To Book | 9.17 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.